When the value-add market stalled in March, Excelsa pivoted to core/core-plus opportunities, first with Aspen at Mercer Crossing, and is now working hard to secure a second Dallas asset.

Blackstone is commencing a go-shop process on behalf of BioMed's current investors.

"Strong and growing capital flows into the life science sector are accelerating innovation and discovery."

For two straight quarters, the sector has seen occupancies decline.